Drugs / Sapu003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07369505 | Dec 2025 → Jun 2026 overdue | breast carcinoma, hepatocellular carcinoma, neuroendocrine neoplasm, renal cell carcinoma +1 | SAPU NANO (US) LLC | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-07-07 | Mateon Therapeutics | Results Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway oncotelic.com ↗
Following completion of the protocol-defined 28-day dose-limiting toxicity (DLT) evaluation period for the initial three-patient cohort, the SRC concluded that no dose-limiting toxicities (DLTs) were observed and recommended advancing the study to the next planned dose level in accordance with the study protocol. |
| 2025-12-04 | Mateon Therapeutics | Results Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine oncotelic.com ↗
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano today announced new biomarker data identifying a molecular signature that predicts sensitivity to Sapu003 , the company's intravenous Deciparticle™ formulation of everolimus. |
| 2025-12-03 | Mateon Therapeutics | Results Oncotelic and Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing oncotelic.com ↗
New tissue-distribution data show that Sapu003, delivered intravenously, eliminates the extreme gastrointestinal accumulation characteristic of oral everolimus. |
| 2025-09-24 | Mateon Therapeutics | Regulatory Sapu Nano oncotelic.com ↗
Sapu Nano, developer of Deciparticle™, today announced that it has received approval from Australia's Human Research Ethics Committee (HREC) to begin enrolling patients in a Phase 1 human clinical trial of Sapu003-an injectable form of Everolimus-for the treatment of breast cancer. |
All press releases naming this drug 10 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sapu003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07369505 ↗ |
| Route | Intravenous | “Sapu003 weekly IV at 5, 7.5 or 10 mg/m²” NCT07369505 ↗ |